A Phase 4 interventional study of Cabozantinib (XL184) 140 mg and Cabozantinib (XL184) 60 mg in Medullary Thyroid Cancer, sponsored by Exelixis. Active, not recruiting at 49 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Exelixis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Carcinoma, Medullary with a site in France — none open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Medullary · France.
Among the 17 studies in Carcinoma, Medullary with a site in France, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2015, is the only one in phase 4, and was the 6th registered.
144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.
Browse Carcinoma, Medullary studies →None of the 17 studies in Carcinoma, Medullary with a site in France is open now. The open studies under Carcinoma, Medullary, anywhere →
Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 247 is above the median of 30 across 100 interventional studies indexed under Carcinoma, Medullary.
Median enrollment 117 across the 13 interventional studies, 31 across the 3 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 17 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 4 studies filed under Carcinoma, Medullary — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Carcinoma, Medullary with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
Drug: Cabozantinib (XL184) 60 mg · Drug: Placebo capsule
Cabozantinib (XL184) 140 mg as tablets and placebo capsules administered orally once a day.
Drug: Cabozantinib (XL184) 140 mg · Drug: Placebo tablet
Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
PFS per BIRC per RECIST 1.1 was measured from randomization until the date of first documented disease progression or date of death from any cause, whichever came first, and was assessed for up to 31 months. The prespecified primary analysis was triggered by the required number of at least 150 events occurring in the ITT population, The data cutoff date for this event-driven analysis in the ITT population was when a total of 155 events were reported. Median PFS was calculated using the Kaplan-Meier estimates.
Time frame: Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months
Objective Response Rate (ORR) Per BIRC Per RECIST 1.1
ORR per BIRC per RECIST 1.1 is the percentage of ITT participants who experienced a best overall response of complete response (CR) or partial response (PR), confirmed ≥ 28 days later, CR defined as disappearance of all non-target lesions. All lymph nodes must have been non-pathological in size (\<10 mm short axis). PR defined as unequivocal progression of non-target lesions. Unequivocal progression was to trump target lesion status. It must have been representative of overall disease status change, not a single lesion increase.
Time frame: Median time of follow-up (from the date of randomization of the first participant through primary data cut off [15 July 2020]) was 30.2 months
| Milestone | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg |
|---|---|---|
| Started | 123 | 124 |
| Received at least 1 dose of study drug | 123 | 124 |
| Completed | 123 | 124 |
| Not completed | 0 | 0 |
PFS per BIRC per RECIST 1.1 was measured from randomization until the date of first documented disease progression or date of death from any cause, whichever came first, and was assessed for up to 31 months. The prespecified primary analysis was triggered by the required number of at least 150 events occurring in the ITT population, The data cutoff date for this event-driven analysis in the ITT population was when a total of 155 events were reported. Median PFS was calculated using the Kaplan-Meier estimates.
| months | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg |
|---|---|---|
| Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 11 (8.3 to 13.6) | 13.9 (9.0 to 16.6) |
ORR per BIRC per RECIST 1.1 is the percentage of ITT participants who experienced a best overall response of complete response (CR) or partial response (PR), confirmed ≥ 28 days later, CR defined as disappearance of all non-target lesions. All lymph nodes must have been non-pathological in size (\<10 mm short axis). PR defined as unequivocal progression of non-target lesions. Unequivocal progression was to trump target lesion status. It must have been representative of overall disease status change, not a single lesion increase.
| percentage of participants | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg |
|---|---|---|
| Objective Response Rate (ORR) Per BIRC Per RECIST 1.1 | 33 (25.09 to 42.40) | 33 (24.88 to 42.08) |
Collected over From first dose to 30 days following last dose (up to a maximum of 61 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib (XL184) 60 mg | 59/123 (48%) | 55/123 (44.7%) | 122/123 (99.2%) |
| Cabozantinib (XL184) 140 mg | 51/124 (41.1%) | 62/124 (50%) | 123/124 (99.2%) |
| Event | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg |
|---|---|---|
| Medullary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/123 | 9/124 |
| PneumoniaInfections and infestations | 5/123 | 5/124 |
| AnaemiaBlood and lymphatic system disorders | 3/123 | 1/124 |
| AstheniaGeneral disorders | 3/123 | 1/124 |
| SepsisInfections and infestations | 3/123 | 2/124 |
| NauseaGastrointestinal disorders | 0/123 | 3/124 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/123 | 3/124 |
| HypocalcaemiaMetabolism and nutrition disorders | 2/123 | 3/124 |
| DiarrhoeaGastrointestinal disorders | 2/123 | 2/124 |
| DeathGeneral disorders | 2/123 | 0/124 |
| Event | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 83/123 | 89/124 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 67/123 | 66/124 |
| Weight decreasedInvestigations | 38/123 | 65/124 |
| FatigueGeneral disorders | 43/123 | 48/124 |
| Decreased appetiteMetabolism and nutrition disorders | 44/123 | 46/124 |
| HypertensionVascular disorders | 25/123 | 42/124 |
| NauseaGastrointestinal disorders | 24/123 | 40/124 |
| Mucosal inflammationGeneral disorders | 23/123 | 38/124 |
| Aspartate aminotransferase increasedInvestigations | 35/123 | 38/124 |
| Alanine aminotransferase increasedInvestigations | 36/123 | 36/124 |
Measured in the Safety Population, which included participants who received any amount of study drug.
| Age, Categorical(Participants) | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 85 | 78 | 163 |
| >=65 years | 38 | 46 | 84 |
| Sex: Female, Male(Participants) | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg | Total |
|---|---|---|---|
| Female | 33 | 50 | 83 |
| Male | 90 | 74 | 164 |
| Ethnicity (NIH/OMB)(Participants) | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 8 |
| Not Hispanic or Latino | 103 | 102 | 205 |
| Unknown or Not Reported | 18 | 16 | 34 |
| Race (NIH/OMB)(Participants) | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 11 | 8 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 92 | 102 | 194 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 18 | 13 | 31 |
| Region of Enrollment(participants) | Cabozantinib (XL184) 60 mg | Cabozantinib (XL184) 140 mg | Total |
|---|---|---|---|
| Romania | 9 | 9 | 18 |
| Hungary | 4 | 1 | 5 |
| Russia | 14 | 16 | 30 |
| Spain | 6 | 12 | 18 |
| Canada | 2 | 1 | 3 |
| Netherlands | 4 | 4 | 8 |
| South Korea | 10 | 7 | 17 |
| Sweden | 5 | 1 | 6 |
| Poland | 13 | 17 | 30 |
| Italy | 9 | 13 | 22 |
| Israel | 3 | 5 | 8 |
| Australia | 19 | 20 | 39 |
| France | 21 | 13 | 34 |
| Croatia | 4 | 5 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Jul 2020, 64 months.
Results were first posted in Sep 2025, 5 years 1 month after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib